Navigation Links
IDM Pharma to Present at BIO InvestorForum in San Francisco
Date:10/4/2007

and the EMEA, and the Company's goal of making L-MTP-PE available to patients as quickly as possible. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE by the first quarter of 2008, if at all, the possibility that such data will not support the benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 8 Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in ... part of the newly created Next Biotech Index of,NYSE ... our company,for this index," said Ronald Lorijn, CEO of ... companies and will help investors to track,the performance of ...
... team is proud to announce,the USDA/CVB has granted ... as well as an autogenous bacterin license utilizing ... approval of our manufacturing facility and our oral ... significant milestone for,our Company, and we look forward ...
... of Molecular Vision today,announces that discussions with Acrongenomics ... ceased. Acrongenomics has been unable to,complete on the ... of,Molecular Vision believes that the best interests of ... a conclusion. Acrongenomics remains a,significant shareholder in Molecular ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Part of Next Biotech Index 2PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations 2
(Date:4/14/2014)... are continuing to unravel the molecular changes that underlie ... infections. , When the bacterium Yersinia pestis enters the ... 100 percent fatal if untreated. The way in which ... kills people in a matter of days has largely ... demonstrating that the presence of a protein called the ...
(Date:4/14/2014)... the decision of whether to get a dog. ... can be even more challenging. Now, a University ... in families of children with autism and found, ... reported the benefits of dog ownership included companionship, ... learn responsibility. , "Children with autism spectrum disorders ...
(Date:4/14/2014)... Think of the pressure change you feel when an elevator ... how you,d feel if that elevator carried you all the ... the blink of an eye. , That,s similar to what ... near a dam. For some, the change in pressure is ... seriously injured. , In an article in the March issue ...
Breaking Biology News(10 mins):Plague alters cell death to kill host 2Dog ownership benefits families of children with autism, MU researcher finds 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5
... of Insect Molecular Biology reports the detailed analyses ... pest, the Pea Aphid. The analyses are based on ... and is a major step in enhancing our understanding of ... significant plant pests. The sequencing of the Pea ...
... have calculated the energy and economic potential of urban ... slurry for generating electricity in Spain. These residues are ... friendly and, in the case of solid urban waste, ... has economic and environmental advantages. "It gives added value ...
... the launch of the first Meteosat in 1977, 33 ... given meteorologists the tools to improve weather forecasting, with ... improving with data from operational satellites, like Meteosat Second ... basis for numerical forecasts, making use of the world,s ...
Cached Biology News:Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 2Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 3Waste could generate up to 7 percent of electricity in Spain 2Waste could generate up to 7 percent of electricity in Spain 3
...
...
... designed to rapidly and reliably amplify ... patented APA Technology. APAgene provides hassle-free, ... competitive price. All necessary ingredients are ... Kit can be used for identifying ...
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: